Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Mechanisms by which PIM kinase modulates the effector function of autoreactive CD8 T cells in type 1 diabetes

Award Number: F30DK132807
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 04/07/2023
PERIOD OF PERFORMANCE END DATE: 04/06/2027

Group Awards By:

View Award Description

Mechanisms by which PIM kinase modulates the effector function of autoreactive CD8 T cells in type 1 diabetes - Project Summary Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by T cell destruction of insulin- producing pancreatic b cells. This results in lifelong dependence on exogenous insulin therapy and increases the risk of complications in many organ systems. Advances in understanding the mechanisms by which T cells mediate their autoimmune functions may provide new therapeutic targets for T1D. It is established that CD4 T cells and CD8 T cells are both required for the development of T1D. Studies found that the cytokine IL-21 functions as a critical signal produced by CD4 T cells to help CD8 T cells destroy insulin-producing b cells. However, the direct effects of IL-21 on β cell-reactive CD8 T cell effector function remain incompletely understood. Therefore, the long-term goal of this project is to elucidate molecular mechanisms regulating autoreactive CD8 T cell function. Preliminary scRNA-seq data presented in this proposal identified Pim1 as a possible modulator of activated diabetogenic CD8 T cell function. PIM1 belongs to a serine/threonine protein kinase family that functions downstream of the JAK-STAT pathway and is involved in regulating many processes including cell survival and metabolism. It was also demonstrated that IL-21 induced the expression of PIM1 and its downstream targets in CD8 T cells, while inhibition of PIM kinase in the presence of IL-21 resulted in reduced expression of PIM1 downstream targets. These data led to the hypothesis that IL-21-induced PIM1 kinase is necessary for supporting the sustained cytolytic function and metabolic demands of autoreactive CD8 T cells that are required for T1D development. Aim 1 will determine the role of PIM1 kinase in β cell-autoreactive CD8 T cell cytolytic function in T1D development. These experiments will determine if PIM1 is necessary and sufficient for T1D development. Additionally, the immunological phenotype of autoreactive CD8 T cells following inhibition and overexpression of PIM1 will be assessed. Aim 2 will elucidate the role of PIM1 kinase in b cell- autoreactive CD8 T cell signal transduction and metabolism in T1D. This project will be conducted at the Medical College of Wisconsin and Versiti Blood Research Institute with multidisciplinary support from experts in immunology and diabetes. Rigorous research and bioinformatic training in addition to presentations at national meetings and publication of manuscripts in immunology and T1D will support the development of an independent, academic physician-scientist. Overall, this proposal will advance knowledge of how b cell-autoreactive CD8 T cells function during the development of T1D. This is in line with the mission of NIDDK, since the results of this project may identify PIM1 as a novel therapeutic target for T1D.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $54,538 )
2025	2025	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	4/1/2025	NON-COMPETING CONTINUATION	$53,974
2025	2025	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	5/29/2025	NON-COMPETING CONTINUATION	$564
														Subtotal = $54,538

Issue Date FY: 2024 ( Subtotal = $53,974 )
2024	2024	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	3/21/2024	NON-COMPETING CONTINUATION	$52,694
2024	2024	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	2	4/29/2024	NON-COMPETING CONTINUATION	$1,280
														Subtotal = $53,974

Issue Date FY: 2023 ( Subtotal = $52,694 )
2023	2023	MEDICAL COLLEGE OF WISCONSIN, INC., THE	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	4/7/2023	NEW	$52,694
2023	2023	MEDICAL COLLEGE OF WISCONSIN, INC., THE	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	4/7/2023	NEW	$0
														Subtotal = $52,694

Grand Total All Awards = $161,206

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanisms by which PIM kinase modulates the effector function of autoreactive CD8 T cells in type 1 diabetes

Award Number: F30DK132807

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 04/07/2023

PERIOD OF PERFORMANCE END DATE: 04/06/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer